文献速递浆细胞疾病造血干细胞移植与细胞治疗

新诊断多发性骨髓瘤年轻成人(年龄≤40岁)接受 upfront 自体干细胞移植后的结局

Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.
PubMed 文献 · Br J Haematol · 2023-06-27

单中心分析纳入117例移植时中位年龄37岁(范围22-40)的新诊断多发性骨髓瘤年轻患者,17例(15%)具有高危细胞遗传学。移植后最佳反应≥CR和≥VGPR分别为56%和77%,中位PFS 43.1个月,中位OS 146.6个月。2010年后移植者PFS和OS优于更早移植者。

要点

  • 年轻MM患者auto-HCT后中位PFS 43.1个月,中位OS 146.6个月。
  • 2010年后移植较更早移植PFS更优(84.9个月 vs 28.2个月)。
  • 移植后最佳反应≥CR与PFS改善相关(HR 0.55)。

核心结论

  • 年轻MM患者auto-HCT后获得持久生存,近年来随着新型抗骨髓瘤药物可及而进一步改善。
  • 移植后缓解深度仍是生存的关键预测因素。

研究设计与样本

  • 单中心分析纳入117例年轻患者,移植时中位年龄37岁(范围22-40)。
  • 17例(15%)患者具有高危细胞遗传学。

主要发现

  • 移植前10%患者达到≥CR,44%达到≥VGPR。
  • 移植后最佳反应时56%和77%患者分别达到≥CR和≥VGPR。
  • 存活者中位随访72.6个月(范围0.9-238.0),中位PFS 43.1个月(95%CI 31.2-65.0),中位OS 146.6个月(95%CI 100.0-208.1)。
  • 2010年后接受auto-HCT者较更早移植者中位PFS更优(84.9个月 vs 28.2个月,p<0.001),中位OS更优(未达到 vs 91.8个月,p<0.001)。
  • 多因素分析中,移植后最佳反应达到≥CR与PFS改善相关(HR 0.55,95%CI 0.32-0.95,p=0.032),达到≥VGPR预测OS更优(HR 0.32,95%CI 0.16-0.62,p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) primarily affects older patients. There are scarce data on the outcomes of young adults undergoing autologous transplantation (auto-HCT). In this single-centre analysis, we included 117 younger patients, with a median age of 37 years (range 22-40) at transplant. Seventeen (15%) patients had high-risk cytogenetics. Before transplant, 10% of patients achieved ≥CR and 44% achieved ≥VGPR. At best post-transplant response, 56% and 77% of patients achieved ≥CR and ≥VGPR respectively. With a median follow-up for survivors of 72.6 months (range 0.9-238.0), median PFS and OS were 43.1 months (95% CI 31.2-65.0) and 146.6 months (95% CI 100.0-208.1) respectively. Patients who underwent auto-HCT after 2010 had better median PFS (84.9 months vs. 28.2 months, p < 0.001) and OS (NR vs. 91.8 months, p < 0.001) compared with those transplanted earlier. In multi-variate analysis, achieving ≥CR as best post-transplant response was associated with improved PFS (HR [95% CI] 0.55 [0.32-0.95], p = 0.032), while achieving ≥VGPR was predictive of superior OS (0.32 [0.16-0.62], p < 0.001). Three patients (3%) developed a second primary malignancy. Younger MM patients had durable survival after auto-HCT, which further improved after the availability of novel anti-myeloma drugs in recent years. Depth of response following transplant remains a key predictor of survival.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Pasvolsky O, Marcoux C, Milton DR, et al. Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol. 2023. PMID: 37376789. doi:10.1111/bjh.18944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。